Prescription drug prices have risen sharply in recent decades in the United States. Underlying this trend is a widening gap between list and net prices for many drugs due to increasing use of rebates. As a result, patients who use expensive drugs with large rebates are paying substantially more because deductibles and coinsurance amounts are typically based on list prices. This problem is particularly important for those with Medicare Part D coverage.
On July 27, the USC-Brookings Schaeffer Initiative for Health Policy will host a webinar to discuss how the increasing reliance on rebates burdens many Medicare patients and policy solutions. Erin Trish will present research on the increasing magnitude of rebates in Part D and the implications for beneficiaries and federal spending. Following the presentation, Paul B. Ginsburg will moderate a panel discussion that will examine alternative solutions to this issue.
Viewers can submit questions for panelists by emailing [email protected] or via Twitter with #DrugRebates.
Tuesday, July 27, 2021 10:30 AM - 11:45 AM Pacific
Panel
Erin Trish, (Introduction) Associate Director of Health Policy, Schaeffer Center for Health Policy and Economics, University of Southern California; Assistant Professor, School of Pharmacy, University of Southern California; Nonresident Fellow, The Brookings Institution
Paul B. Ginsburg, (Moderator) Professor of Health Policy, Price School of Public Policy, University of Southern California; Director of Public Policy, USC Schaeffer Center; Nonresident Senior Fellow, The Brookings Institution; Former Director, USC-Brookings Schaeffer Initiative for Health Policy
Panelists
- Anna Anderson-Cook, Senior Fellow, Arnold Ventures
- John O’Brien, President and Chief Executive Officer, National Pharmaceutical Council
- Matt Perlberg, Senior Vice President, Supply Chain at Express Scripts